Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash flows from operating activities
Net (loss) income	$ (258,869)	$ (623,035)
Adjustments to reconcile net (loss) income to net cash used in operating activities
Depreciation	9,949	0
Amortization	83,906	106,203
Lease expense	0	5,172
Deferred income tax benefit	0	0	$ (2,735)
Shares issued for interest	0	62,100
Foreign exchange loss	0	24,725
Changes in operating assets and liabilities:
Accounts receivable	29,380	0
Prepaid expenses and other assets	966	0
Operating lease liability	11,068	0
Other receivable	(79,296)	42,730
Accounts payable	4,073	27,522
Accounts payable – related parties	(69,585)	0
Accrued interest – related and non-related parties	124,235	186,505
Operating lease payments	(5,735)	0
Governmental assistance payable	0	0
Accrued expenses	76,042	31,200
Net cash used in operating activities	(58,020)	(61,128)
Cash flows from investing activities
Advances to CEN Biotech Ukraine LLC	0	(50,000)
Net cash provided by (used in) investing activities	0	50,000
Cash flows from financing activities
Repayment of convertible notes	0	(110,000)
Issuance of convertible notes - related parties	0	0
Net cash provided by financing activities	0	110,000
Net increase (decrease) in cash and cash equivalents	(58,020)	(1,128)
Cash and cash equivalents, beginning of year	193,198	1,908	1,908
Cash and cash equivalents, end of year	135,178	780	$ 193,198
CEBA, Loan Payable [Member]
Changes in operating assets and liabilities:
Ceba Loan Payable	$ 15,848
CEBA, Loan Payable [Member] | CEBA, Loan Payable [Member]
Changes in operating assets and liabilities:
Ceba Loan Payable		$ 0